AbbVie to Acquire Aliada Therapeutics, Appoints Roopal Thakkar as Executive Vice President and Chief Scientific Officer
Acquiring Company
AbbVie Inc.
Acquired Company
Aliada Therapeutics
North ChicagoBostonManufacturingBiotechnologyHealthcareHealth CareTherapeuticsPharmaceuticalBiopharmaBiotechnologyDescription
AbbVie has announced the acquisition of Aliada Therapeutics, a biotechnology company specializing in therapies for CNS diseases. This acquisition aims to advance ALIA-1758, a potential disease-modifying therapy for Alzheimer's disease, leveraging Aliada's novel BBB-crossing technology and strengthening AbbVie's R&D capabilities for neurological disorders.
Don't miss AbbVie Inc.'s next move
Get an email the moment AbbVie Inc. makes an acquisition, hires an exec, or expands, usually minutes after it happens.
One email per event. Unsubscribe anytime.
M&A Insights
Based on deal dataFrequently asked
Who acquired Aliada Therapeutics?
Aliada Therapeutics was acquired by AbbVie Inc., based in North Chicago. The deal was reported on September 1, 2026. Venture capital subsidiary of Abbvie AbbVie Inc. is publicly traded (ABBV) and operates in Manufacturing.
When did AbbVie Inc. acquire Aliada Therapeutics?
AbbVie Inc.'s acquisition of Aliada Therapeutics was reported on September 1, 2026. AbbVie has announced the acquisition of Aliada Therapeutics, a biotechnology company specializing in therapies for CNS diseases. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Aliada Therapeutics do?
Biologics are transforming the treatment of numerous diseases, but many CNS diseases remain largely out of reach due to the challenge of crossing the blood-brain barrier and navigating the brain’s unique immune environment. It is privately held, operating in Biotechnology, and is based in Boston.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.